CSL

Responsable Hospitalier Maladies Rares - Hauts-de-France / Normandie

France

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Healthcare, Rare DiseasesIndustries

Position Overview

  • Location Type: Onsite
  • Employment Type: Full Time
  • Salary: Not specified

This role requires a deep understanding of rare diseases and their ecosystem, including diagnostic procedures, therapeutic decisions, and treatment selection. The Hospital Manager for Rare Diseases will play a central role in planning, executing, and implementing the launch and commercialization of products for rare diseases within a designated territory. This individual will be responsible for deploying the local commercial strategy and serving as the primary commercial contact for all clients. They will utilize an omnichannel approach to manage clients effectively, ensuring adherence to pharmaceutical regulations and legal/regulatory obligations, company strategy, and internal operating procedures and professional ethics.

Requirements

  • Knowledge of rare diseases and their ecosystem.
  • Understanding of diagnostic procedures, therapeutic decisions, and treatment selection.
  • Experience in commercial strategy development and execution.
  • Strong communication and interpersonal skills.
  • Ability to work collaboratively with cross-functional teams.
  • Commitment to ethical and compliant practices.
  • Familiarity with pharmaceutical regulations and legal/regulatory obligations.

Responsibilities

  • Contribute to sales forecasting by focusing on key expert centers, tracking and managing performance against sector plans and KPIs, adhering to Vifor France's code of conduct and ethical standards.
  • Develop, direct, and execute the local territory plan with specific objectives and targets.
  • Collaborate closely with market access functions to ensure patient access to treatment locally.
  • Encourage a data-driven culture utilizing customer insights, data, dashboards, and CRM tools to guide effective commercial decisions.
  • Maintain strategic and tactical development relevance, significance, and commercial advantage.
  • Create a cross-functional work environment with various company services.
  • Develop and implement a customer-centric approach and be the lead/responsible for it.
  • Maintain a thorough understanding of clients, patient care, and the competitive landscape.
  • Ensure exemplary customer experience and Vifor France's image as a trusted partner for patients.
  • Contribute to the development of access strategies and pathways for rare disease treatments.

Application Instructions

  • Not specified

Company Information

  • Company: Vifor France (Implied)
  • Industry: Pharmaceutical (Focus on rare diseases)

Skills

Rare diseases knowledge
Diagnostic procedures
Therapeutic decisions
Treatment selection
Commercial strategy development
Communication
Interpersonal skills
Cross-functional collaboration
Pharmaceutical regulations
Legal/regulatory compliance
Data-driven decision making
CRM tools

CSL

Develops biotherapies and influenza vaccines

About CSL

CSL develops and delivers biotherapies and influenza vaccines, focusing on rare and serious diseases. Their products include plasma-derived and recombinant therapies, which are created through extensive research and development. CSL serves a wide range of clients, including healthcare providers and governments, across the Americas, Asia Pacific, and Europe. What sets CSL apart from competitors is its comprehensive portfolio and commitment to addressing rare diseases, alongside a strong emphasis on diversity and inclusion within its workforce. The company's goal is to save lives and protect health through its innovative therapies and vaccines.

Parkville, AustraliaHeadquarters
1916Year Founded
$2,628.7MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Emerging synthetic biomaterials may reduce demand for traditional plasma therapies.
Jumar Bioincubator could increase local competition in the biotech sector.
CSL may need to adapt to the rising effectiveness of cell-based influenza vaccines.

Differentiation

CSL offers the broadest range of plasma-derived and recombinant therapies globally.
CSL's self-amplifying mRNA COVID-19 vaccine provides longer immunity at lower doses.
CSL's MF59® adjuvant enhances immune response, crucial for pandemic preparedness.

Upsides

CSL's garadacimab could be the first monthly treatment for hereditary angioedema.
CSL's cell-based influenza vaccine shows higher effectiveness over egg-based vaccines.
CSL's gene therapy HEMGENIX® offers a one-time treatment for haemophilia B.

Land your dream remote job 3x faster with AI